Pradžia › Neuroblastoma › Masčusetsas
Neuroblastoma klinikiniai tyrimai Masčusetsas
13 tyrimai dėl Neuroblastoma ieško dalyvių vietose Masčusetsas.
Miestai Masčusetsas
Oficialus tyrimo tekstas (anglų kalba)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai3 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-10-02 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Renkami dalyviai
Visi amžiai · Visoms lytims · Atnaujinta 2026-10-01 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
Renkami dalyviai1 fazė
9 Months – 30 Years · Visoms lytims · Atnaujinta 2026-09-03 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai3 fazė
365 Days – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Amžius nuo 2 iki 21 · Visoms lytims · Atnaujinta 2026-08-11 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-07-22 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
Renkami dalyviai2 fazė
Amžius nuo 1 iki 31 · Visoms lytims · Atnaujinta 2026-07-20 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-07-14 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
Renkami dalyviaiStebimasis tyrimas
31 Days – 99 Years · Visoms lytims · Atnaujinta 2026-03-23 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai
Iki 17 metų · Visoms lytims · Atnaujinta 2026-02-10 · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
12 Months – 29 Years · Visoms lytims · Atnaujinta 2025-12-26 · NCT06803875Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.